PubMed Health⌕ Search

Biomedical subjects

G Hoerni-Simon

Publications and source records attributed to G Hoerni-Simon.

At least 37 records · Page 2Linked to original sources
PubMed1979

Successful maintenance immunotherapy by BCG of non-Hodgkin's malignant lymphomas: results of a controlled trial.

Forty-eight patients less than 65 years old, suffering non-Hodgkin's malignant lymphomas with one or more criteria of poor prognosis, were priorly placed in complete remission by an association of chemo + radio + chemotherapy. They were then randomized to receive either BCG in weekly scarifications for 3 years or no further treatment. Five patients were excluded (four after pathological reassessment); 43 are thus evaluable. There were 13 relapses out of 23 control patients and three relapses out of 20 treated patients (0.01 less than P less than 0.025). This difference is more distinct for clinical stages I and II (0.01 less than P less than 0.025) than for stages III and IV (not significant). Eight patients died in the control group whereas there was only one death in the treated group (0.025 less than P less than 0.05). These results indicate than BCG is useful in maintaining remission in about 40% of the cases and also in increasing their survival, especially in patients with clinical stages I or II.

Adolescent↗
PubMed1979

Total body irradiation (T.B.I.). Preliminary results of a new technique in 30 patients with hematologic malignancy.

The authors present the preliminary results of a new technique of total body irradiation (T.B.I.) used in 30 patients with hematological malignancy. The schedule proposed is easy to use and reproducible. The clinical and hematologic tolerance is good even for patients having had previous cyclic polychemotherapy and/or large-field irradiation. Low-grade non-Hodgkin lymphomas previously nontreated appear to be the best indication. Further investigations have to be performed particularly to specify the interest of combining T.B.I. and chemotherapy or T.B.I. and radiotherapy in the treatment of non-Hodgkin lymphomas.

Adult↗
PubMed1978

Malignant lymphoplasmacytoid lymphomas. Clinical and evolutive data.

A series of 31 cases of malignant lymphoplasmacytoid lymphomas (excluding Waldenström disease) is analyzed. Two-thirds of the patients initially had localizations elsewhere than in the lymph nodes and presented clinical stage I or II. The median survival is around 4 years and is particularly favorable for stage I and II patients who have received an association of radiotherapy and systematic chemotherapy; the estimated "cure rate" for these patients is around 80%.

Adult↗
PubMed1978

[Immunoblastic lymphosarcomas. Clinicopathological aspects and course. Retrospective analysis of a series of 50 patients (author's transl)].

The immunoblastosarcoma (IB) was preceeded by another pathological state in almost one third of patients. The clinical picture was often very typical, with large inflammatory node involvement. In one third of cases, the initial site of the tumor was not nodal, but in Waldeyer's ring or a non-lymphoid organ. Analysis of topographic extension indicates a weak propensity to dissemination. The tissues which are the more frequent site of secondary invasion were the lung parenchyma and the subcutaneous tissue. The course was rapid, almost always fatal. Only a combination of radiotherapy and chemotherapy would seem capable of eradicating the tumour. On the basis of all these characteristics, the IB has a special place alongside other non-Hodgkin lymphomas and they may be individualised histologically. These cases are in general in agreement with the little data published in the literature.

Adult↗
PubMed1978

BCG in the immunotherapy of non-Hodgkin's malignant lymphomas: preliminary results of a controlled trial.

Thirty-three patients exhibiting non-Hodgkin's malignant lymphoma with one or more criteria of poor prognosis and in whom complete remission had been induced by an association of chemo + radio + chemotherapy were randomized to either receive BCG or no further treatment. The present results indicate that BCG may be useful to maintain remission in about one-third of the patients, but these results are not yet significant.

Antineoplastic Agents↗
PubMed1978

[Induction chemotherapy of non-Hodgkin malignant lymphomas. Results of a controlled trial comparing two quadruple associations (author's transl)].

Two types of chemotherapy have been compared in a randomized trial to treat non-Hodgkin malignant lymphomas. 66 patients were included in this study, but only 40 were evaluable after a histologic review of all cases. Treatment were an association of cyclophosphamide, vincristine, prednisone and doxorubicine or VM 26. Patients received only one induction chemotherapy course during 15--20 days. Results were evaluated immediately at the end of the course. Side-effects were mild. Efficacy was about the same with the two protocols: 35 patients out of 40 experienced a remission of more than 50% (among them 8 experienced a complete remission). These results are better than previous one obtained with cyclophosphamide, vincristine and prednisone only. It is concluded that this type of treatment is well tolerated, quickly efficient and useful before treating patients with radiotherapy or long-term chemotherapy.

Antineoplastic Agents↗
PubMed1978

Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects.

The hematologic effects of combined chemotherapy and irradiation were analyzed in 70 patients with Hodgkin's disease stage I and II. The schedule used was as follows: one cycle of 15--21 days of chemotherapy immediately followed by irradiation, including mantle and lumboaortic fields. After a rest of one month, another cycle of the same chemotherapy was applied. The erythrocytes varied slightly; the leukocytes decreased during chemotherapy and were stable or increased slightly during irradiation. Platelets decreased slightly during chemotherapy and more markedly during irradiation. No major side effects were observed, and the regimen appeared well tolerated.

Adolescent↗
PubMed1976

[Treatment of Hodgkin's disease, clinical stage I and II. Results obtained in 100 patients by combination of 1 or 2 cycles of chemotherapy with radiotherapy].

The results obtained by chemo+radiotherapy in 100 patients with Hodgkin's disease at stage I or II as defined by clinical and radiological staging are analysed. All patients were treated by chemotherapy followed by radiotherapy; 74 received a complement chemotherapy after the radiotherapy. Statistical analysis emphasizes the usefulness of associating two cycles of chemotherapy with the classical radiotherapy. With this treatment which gives a constant remission rate of about 90% a long-term chemotherapy is no longer necessary and the interest of exploratory laparotomy becomes negligible.

Adolescent↗
PubMed1975

[Infectious complications of malignant lymphomas. Evaluation of 411 infections observed in 629 patients].

The main clinical and paraclinical characteristics of 411 infections which occured in 629 patients with malignant lymphoma, treated between 1960 and 1973, are reported here. The theoretical interest of such cases is emphasized, they permit one to contrast Hodgkin's disease with other forms of lymphoma in view of the very marked paraneoplastic immune deficiency in the first group. The practical, diagnostic and therpeutic problems raised are exceptionally difficult and may become even more simple with more efficacious anticancer therapy which, curing more regularly patients from their blood disease, avoids the factors which favour these infections.

Adolescent↗